Governance Legend Biotech Corporation

LEGN

US52490G1022

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 16:00:00 2026-02-13 EST			5-day change	1st Jan Change
17.58 ^USD	-2.66%		+2.27%	-19.14%

02-12	Sector Update: Health Care Stocks Rise Late Afternoon	MT
02-12	Sector Update: Health Care	MT

Executive Committee: Legend Biotech Corporation

Manager

Positions heldSince

Ying Huang

53 year

Chief Executive Officer

2020-09-20

Jim Pepin

General Counsel

2023-10-31

Elaine Qian

Human Resources Officer

Mythili Koneru

48 year

Chief Tech/Sci/R&D Officer

2023-04-10

Tracy Luo

Chief Tech/Sci/R&D Officer

2018-04-30

Guowei Fang

Chief Tech/Sci/R&D Officer

2022-02-28

Jessie Yeung

41 year

Investor Relations Contact

2018-12-31

Yuhong Qiu

General Counsel

2018-04-30

Composition of the Board of Directors: Legend Biotech Corporation

Director

CommitteesSince

Fang Liang Zhang

61 year

Chairman

2022-08-01

Ye Wang

57 year

Compensation Committee	2022-08-01
Nominating Committee	2025-03-10
Audit Committee Chair	2025-05-28
Governance Committee Chair	2022-08-01
Nominating Committee Chair	2022-08-01

Wai Man Yau

50 year

Governance Committee
Nominating Committee
Audit Committee Chair	2020-04-30

Corazon Sanders

69 year

Audit Committee
Compensation Committee

Xiao Hui Ji

64 year

Audit Committee
Compensation Committee Chair	2020-04-30

Patrick Casey

70 year

Governance Committee
Nominating Committee

Tomas Jan Heyman

70 year

Governance Committee

2023-05-30

Li Zhu

76 year

Director/Board Member

2020-11-22

Ying Huang

53 year

Director/Board Member

2021-12-29

Li Mao

69 year

Director/Board Member	2022-08-01
Independent Dir/Board Member	2022-08-01

Peter Salovey

68 year

Director/Board Member	2024-08-08
Independent Dir/Board Member	2024-08-08

Latest Appointments: Legend Biotech Corporation

02-06	Legend Biotech Corporation Announces Board and Audit Committee Changes, Effective February 2, 2026	CI
01-23	Legend Biotech Corporation Announces Changes to Board of Directors and Audit Committee, Effective January 20, 2026	CI
25-10-14	Cabaletta Bio, Inc. Announces the Appointment of Steve Gavel as Chief Commercial Officer, Effective from October 14, 2025	CI
25-08-18	Legend Biotech Corporation Announces Chief Financial Officer Changes	CI
25-08-18	Legend Biotech appoints Carlos Santos as chief financial officer	RE
25-08-18	Legend Biotech Names Carlos Santos CFO	MT
25-08-18	Legend Biotech Corporation Appoints Carlos Santos as the Company?s Principal Financial Officer and Principal Accounting Officer, Each Effective as of August 18, 2025	CI

More news

Former Officers and Directors: Legend Biotech Corporation

Insider

Positions held

SinceUntil

Lori Macomber

Comptroller/Controller/Auditor	2019-08-31	2020-02-29
Director of Finance/CFO	2022-05-08	2025-01-01
Corporate Officer/Principal	2020-02-29	2022-05-08

Steven J. Gavel

Corporate Officer/Principal

2018-07-31

2024-12-31

Tina Carter

Public Communications Contact

2021-06-30

2023-11-30

Liz Gosen

Chief Tech/Sci/R&D Officer

2019-04-30

2023-11-30

Marc L. Harrison

General Counsel

2021-12-31

2023-06-30

Lida Pacaud

Chief Tech/Sci/R&D Officer

2020-12-31

2023-05-31

Meeta Chatterjee

Corporate Officer/Principal

2019-02-28

2022-10-31

Robert Sexton

Corporate Officer/Principal

2019-03-31

2022-09-30

Frank Fan

Chief Tech/Sci/R&D Officer	2013-12-31	2022-03-29
Founder	-	2022-03-29

John Tomtishen

Corporate Officer/Principal

2021-10-10

Crystal Chen

Public Communications Contact

2020-12-31

Syed Rizvi

Chief Tech/Sci/R&D Officer

2018-05-31

2020-10-31

Yuan Xu

Director/Board Member	2018-02-28	2020-07-31
Chief Executive Officer	2018-02-28	2020-07-31

Qi Pan

Chief Tech/Sci/R&D Officer

2017-07-31

2017-12-31

Zuie Chin Huang

Founder

Joanne Choi

Investor Relations Contact

Age distribution of managers

Parity Men Women

Male	16
Female	3

Of which Executive Committee

Male	6
Female	2

Of which Directors

Male	10
Female	1

Revisions

Révisions CA 1 an

Révisions CA 4 mois

Révisions CA 1 mois

Révisions BNA 1 an

Révisions BNA 4 mois

ESG MSCI

Environnement

Social

Gouvernance

Polémique

Controverses Ethiques

Controverses sur les droits de l'Homme

Controverses Subventions fiscales

Conforme à la finance Islamique

Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.

Employees

2,900

Sector

Biotechnology & Medical Research

Calendar

03-17 - Q4 2025 Earnings Release (Projected)

More about the company